Status:
RECRUITING
Ketoconazole Contributes to Cryptorchidism Outcome Via Modulating Macrophage Trem2
Lead Sponsor:
Affiliated Hospital of Nantong University
Conditions:
Cryptorchidism
Eligibility:
MALE
8-13 years
Phase:
NA
Brief Summary
Reduced hormone insulin-like 3, exclusively secreted by Leydig cells, has been identified as the recognized mechanism for cryptorchidism. Testicular macrophages residing in the testicular interstitium...
Eligibility Criteria
Inclusion
- 1\. Termination of pregnancy is not related to the health of the fetus.
- 2\. The fetus is intact in development and free of malformations and abnormalities.
- 3\. Estimation of gestational age based on parietal-rump length must be between 8 and 13 weeks of gestation.
Exclusion
- 1\. The termination of pregnancy is related to the health of the fetus
- 2\. The fetus is not intact in development.
- 3\. The fetus has malformations, abnormalities
- 4\. Estimation of gestational age based on parietal-rump length must not be within 8-13 weeks of gestation.
Key Trial Info
Start Date :
February 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06560086
Start Date
February 3 2024
End Date
December 31 2024
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Affiliated hospital of nantong university
Nantong, Jiangsu, China, 226001